News

Details

Published: 17 April 2020

• portfolio-news

Dr. Dukes has amassed over 20 years in leadership roles at large pharmaceutical and biotechnology companies. As Themis transitions towards rapidly ramping up the development of a coronavirus vaccine candidate towards the clinic in response to the global pandemic and being prepared to supply the initial stockpiles of its vaccine, Dr. Dukes’ background will further enhance the range of experience on the Company’s Board.

Details

Published: 16 April 2020

• portfolio-news

STipe Therapeutics announced the appointment of seasoned industry experts: “Both Natalie and Richard are highly experienced industry executives who bring a wealth of international drug development and approval expertise to STipe,” said Dr Claus Elsborg Olesen (CEO). “We are developing novel cancer therapies and I look forward to drawing on their extensive experience as we prepare for the selection of a lead candidate for clinical development.” 

Details

Published: 15 April 2020

• portfolio-news

Wellington Partners today announced a seed investment into newly founded SIRS Therapeutics, Munich, Germany. With the investment, SIRS has secured the joint ownership with Austrian F4 Pharma of all rights on FX06, a fibrin-derived peptide for treatment of patients with acute respiratory distress syndrome (ARDS) and systemic inflammatory response syndrome (SIRS), including patients with underlying COVID-19 infection.